

Exciting Enhancements to the Roche Agreement

Oncology Associates is pleased to announce the following improvements to the Roche agreement for Kytril:

- Start Date of July 1, 2004
- The minimum annual 5HT₃ DDD dollars required for Super Tier pricing shall be significantly lowered from \$1,000,000 to \$500,000.
- Kytril Market Share will be determined using DDD Dollars and is calculated as the sum of Kytril sales divided by the sum of all 5HT₃ Market sales.

Kytril® Injection is available as follows:

NDC	Package Size	Strength
00004-0239-09	1mg/mL 1mL Single Dose Vial	1mg/mL
00004-0240-09	1 mg/mL 4 mL Multi Dose Vial	1mg/mL

Please contact Oncology Associates at **888-732-7352** for additional information on how you can get the greatest benefit out of your Roche agreement.